MX2020003947A - Anticuerpo anti-cd3 y composicion farmaceutica para el tratamiento del cancer que comprende el mismo. - Google Patents

Anticuerpo anti-cd3 y composicion farmaceutica para el tratamiento del cancer que comprende el mismo.

Info

Publication number
MX2020003947A
MX2020003947A MX2020003947A MX2020003947A MX2020003947A MX 2020003947 A MX2020003947 A MX 2020003947A MX 2020003947 A MX2020003947 A MX 2020003947A MX 2020003947 A MX2020003947 A MX 2020003947A MX 2020003947 A MX2020003947 A MX 2020003947A
Authority
MX
Mexico
Prior art keywords
antibody
pharmaceutical composition
same
cancer treatment
cancer
Prior art date
Application number
MX2020003947A
Other languages
English (en)
Inventor
Eun Jung Song
Hye Ji Choi
Ki Su Kim
Jun Hong Jeong
Hyung Kwon Lim
Jong Wha Won
Ae Rin Yoon
Ok Jae Lim
Yun Jung Lee
Original Assignee
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp filed Critical Green Cross Corp
Publication of MX2020003947A publication Critical patent/MX2020003947A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un anticuerpo anti-CD3 y a una composición farmacéutica para el tratamiento del cáncer que comprende el mismo. El anticuerpo de acuerdo con la presente invención tiene una alta afinidad y especificidad por CD3 y, por lo tanto, puede usarse eficazmente en la prevención o el tratamiento del cáncer.
MX2020003947A 2017-10-20 2018-10-22 Anticuerpo anti-cd3 y composicion farmaceutica para el tratamiento del cancer que comprende el mismo. MX2020003947A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170136564A KR101973060B1 (ko) 2017-10-20 2017-10-20 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물
PCT/KR2018/012492 WO2019078697A2 (ko) 2017-10-20 2018-10-22 항" cd3항체 및 이를포함하는 암치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
MX2020003947A true MX2020003947A (es) 2020-08-03

Family

ID=66173409

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003947A MX2020003947A (es) 2017-10-20 2018-10-22 Anticuerpo anti-cd3 y composicion farmaceutica para el tratamiento del cancer que comprende el mismo.

Country Status (13)

Country Link
US (2) US11498965B2 (es)
EP (1) EP3699192A4 (es)
JP (1) JP7024072B2 (es)
KR (1) KR101973060B1 (es)
CN (1) CN111315779A (es)
AU (1) AU2018353787B2 (es)
BR (1) BR112020007770A2 (es)
CA (1) CA3077007C (es)
EA (1) EA202090944A1 (es)
IL (1) IL274007A (es)
MX (1) MX2020003947A (es)
SG (1) SG11202003273PA (es)
WO (1) WO2019078697A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230071196A1 (en) * 2019-05-21 2023-03-09 Novartis Ag Variant cd58 domains and uses thereof
CA3196933A1 (en) * 2020-09-29 2022-04-07 Innovent Biologics (Suzhou) Co., Ltd. Anti-cd3 antibody and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2480263A1 (en) 2002-03-26 2003-10-09 Trubion Pharmaceuticals, Inc. Activation of tumor-reactive lymphocytes via antibodies or genes recognizing cd3 or 4-1bb
JP5686953B2 (ja) * 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
US8846042B2 (en) * 2011-05-16 2014-09-30 Fabion Pharmaceuticals, Inc. Multi-specific FAB fusion proteins and methods of use
EP2714733B1 (en) * 2011-05-21 2019-01-23 MacroGenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CN113248615A (zh) 2013-07-05 2021-08-13 根马布股份公司 人源化或嵌合cd3抗体
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
DK3083689T3 (da) 2013-12-17 2020-08-03 Genentech Inc Anti-CD3-antistoffer og fremgangsmåder til anvendelse
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
EP2982693A1 (en) 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
AU2017213886B2 (en) 2016-02-04 2024-03-07 The California Institute For Biomedical Research Humanized anti-CD3 antibodies, conjugates and uses thereof
WO2018199593A1 (ko) 2017-04-24 2018-11-01 재단법인 목암생명과학연구소 Her3 및 cd3에 결합하는 이중특이적 항체

Also Published As

Publication number Publication date
WO2019078697A8 (ko) 2020-04-09
CA3077007C (en) 2023-04-18
US20200317779A1 (en) 2020-10-08
EP3699192A2 (en) 2020-08-26
AU2018353787B2 (en) 2022-02-24
BR112020007770A2 (pt) 2020-10-20
EA202090944A1 (ru) 2020-07-16
EP3699192A4 (en) 2021-10-20
JP2021501571A (ja) 2021-01-21
JP7024072B2 (ja) 2022-02-22
CN111315779A (zh) 2020-06-19
US20230192851A1 (en) 2023-06-22
WO2019078697A2 (ko) 2019-04-25
CA3077007A1 (en) 2019-04-25
KR101973060B1 (ko) 2019-04-26
WO2019078697A3 (ko) 2019-07-04
US11498965B2 (en) 2022-11-15
AU2018353787A1 (en) 2020-05-21
SG11202003273PA (en) 2020-05-28
IL274007A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
PH12019502875A1 (en) Antibody molecules to cd73 and uses thereof
CO2020016559A2 (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
EA202091540A1 (ru) Антитела к lilrb2
BR112018070919A2 (pt) anticorpos anti-tim-3 e composições
CL2019001660A1 (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas.
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
EA201691824A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
CL2020000233A1 (es) Anticuerpos anti-cd137.
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2020003943A (es) Anticuerpo anti-msln y composicion farmaceutica para el tratamiento del cancer que comprende el mismo.
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
CL2021001246A1 (es) Moduladores de expresión irf5.
CO2020007601A2 (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis
MX2020003947A (es) Anticuerpo anti-cd3 y composicion farmaceutica para el tratamiento del cancer que comprende el mismo.
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
CL2020002347A1 (es) Nuevo compuesto y composición farmacéutica que lo comprende
CO2020003134A2 (es) Moduladores de la expresión de enac
UY38472A (es) Moduladores de la expresión de foxp3